Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease

Human Pathology

Volumn 43, Issue 6, 2012, Pages 790-800

  Guy, Cynthia D ^a   Suzuki, Ayako ^a   Burchette, James L ^a   Brunt, Elizabeth M ^b   Abdelmalek, Manal F ^a   Cardona, Diana ^a   McCall, Shannon J ^a   Ünalp, Aynur ^c   Belt, Patricia ^c   Ferrell, Linda D ^d   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ballooned hepatocytes; Endoplasmic reticulum stress; Immunohistochemistry; Insulin resistance; Intermediate filaments; Nonalcoholic steatohepatitis

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; UBIQUITIN;

ADULT; ARTICLE; CELL SIZE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL DAMAGE; MALE; NONALCOHOLIC FATTY LIVER; STAINING;

BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; KERATIN-8; MALE; MIDDLE AGED; UBIQUITIN;

EID: 84861200682     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.07.007     Document Type: Article

References (26)

1. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, and A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419 (Pubitemid 29258890)
2. A.J. Sanyal AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 2002 1705 1725 (Pubitemid 35231670)
3. A.J. McCullough Update on nonalcoholic fatty liver disease J Clin Gastroenterol 34 2002 255 262 (Pubitemid 34177381)
4. L.A. Adams, and K.D. Lindor Nonalcoholic fatty liver disease Ann Epidemiol 17 2007 863 869 (Pubitemid 47588954)
5. B.Q. Starley, C.J. Calcagno, and S.A. Harrison Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection Hepatology 51 2010 1820 1832
6. C. Soderberg, P. Stal, and J. Askling Decreased survival of subjects with elevated liver function tests during a 28-year follow-up Hepatology 51 2010 595 602
7. D.E. Kleiner, E.M. Brunt, and M. Van Natta Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321 (Pubitemid 40770284)
8. E.M. Brunt Nonalcoholic steatohepatitis Semin Liver Dis 24 2004 3 20 (Pubitemid 38496045)
9. K. Zatloukal, S.W. French, and C. Stumptner From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res 313 2007 2033 2049 (Pubitemid 46842981)
10. C. Lackner, M. Gogg-Kamerer, K. Zatloukal, C. Sumptner, E.M. Brunt, and H. Denk Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis J Hepatol 48 2008 821 828
11. P. Puri, F. Mirshahi, and O. Cheung Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease Gastroenterology 134 2008 568 576 (Pubitemid 351173040)
12. Nonalcoholic steatohepatitis clinical research network Hepatology 37 2003 244
13. E.M. Brunt Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity? Liver 19 1999 263 264 (Pubitemid 29359088)
14. M.B. Omary, N.O. Ku, P. Strnad, and S. Hanada Toward unraveling the complexity of simple epithelial keratins in human disease J Clin Invest 119 2009 1794 1805
15. M. Harada, S. Hanada, D.M. Toivola, N. Ghori, and M.B. Omary Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasomal inhibitor-mediated formation Hepatology 47 2008 2026 2035 (Pubitemid 351945569)
16. P. Strnad, G.Z. Tao, and P. So "Toxic memory" via chaperone modification is a potential mechanism for rapid Mallory-Denk body reinduction Hepatology 48 2008 931 942
17. S. Caldwell, Y. Ikura, and D. Dias Hepatocellular ballooning in NASH J Heptatol 53 2010 719 723
18. U. Ozcan, Q. Cao, and E. Yilmaz Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 306 2004 457 461 (Pubitemid 39372439)
19. H.L. Kammoun, H. Chabanon, and I. Hainault GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice J Clin Invest 119 2009 1201 1215
20. K. Yoshiuchi, H. Kaneto, and T.A. Matsuoka Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice Endocr J 56 2009 1103 1111
21. D.T. Rutkowski, J. Wu, and S.H. Back UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators Dev Cell 15 2008 829 840
22. A.E. Feldstein, A. Canbay, and P. Angulo Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443 (Pubitemid 36929425)
23. P. Strnad, G.Z. Tao, and Q. Zhou Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models Gastroenterology 134 2008 1169 1179 (Pubitemid 351451981)
24. R. Moll, M. Divo, and L. Langbein The human keratins: biology and pathology Histochem Cell Biol 129 2008 705 733
25. N.O. Ku, P. Strnad, B.H. Zhong, G.Z. Tao, and M.B. Omary Keratins let liver live: mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies Hepatology 46 2007 1639 1649 (Pubitemid 350155545)
26. K. Zatloukal, C. Stumptner, and M. Lehner Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratins 18 determines the ability of hepatocytes to form Mallory bodies Am J Pathol 156 2000 1263 1274 (Pubitemid 30660005)